CMIC : Notice of Revision of Full-Year Earnings Forecast
July 30, 2021 at 02:39 am EDT
Share
July 30, 2021
To the press and whom it may concern,
Company name: CMIC Holdings Co., Ltd.
Representative: Kazuo Nakamura, Representative Director and CEO (TSE 1st Section Code No. 2309)
Inquiries: Wataru Mochizuki, Corporate Director and CFO (Phone: +81-3-6779-8000)
Notice of Revision of Full-Year Earnings Forecast
Tokyo, July 30, 2021 - CMIC HOLDINGS Co., Ltd. (the "Company") today announced the revisions to the forecasts of the full-year consolidated results for the fiscal year ending September 2021 announced on November 6, 2020 as follows.
Notes
1. Revision of FY2021 Full-year Forecast (October 1, 2020 to September 30, 2021)
Operating
Ordinary
Profit
Earnings per
Sales
attributable to
income
income
owners of
share
parent
Original forecast
Millions of yen
Millions of yen
Millions of yen
Millions of yen
Yen
80,000
3,300
3,100
1,650
91.21
(Announced November 6, 2020)
(A)
New revised Forecast
82,000
3,500
3,600
1,700
93.97
(B)
Increase (B-A)
2,000
200
500
50
-
Rate of change (%)
2.5
6.1
16.1
3.0
-
(Reference)
Results for the previous fiscal
76,098
2,605
2,867
1,505
83.27
year
(FY2020)
(Reasons for amendment)
Sales in the fiscal year ending in September 2021 is expected be ¥82,000 million, operating income is expected to be ¥3,500 million, ordinary income is expected to be ¥3,600 million, and profit attributable to owners of parent is expected to be ¥1,700 million.
As a result of the semi-state of emergency and state of emergency coronavirus measures, while there is delay in data collection or decline in contract production volume following the reduced pharmaceutical drug sales volume, we expect to see the growth of vaccination support operations for municipalities.
Attachments
Original document
Permalink
Disclaimer
CMIC Holdings Co. Ltd. published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 06:38:06 UTC.
CMIC HOLDINGS Co., Ltd. mainly provides pharmaceutical development support services. The Contract Research Organization (CRO) segment offers monitoring, data management, pharmaceutical consulting and nonclinical services. The Contract Manufacturing Organization (CMO) segment is engaged in the entrusted manufacture of drugs for pharmaceutical companies. The Contract Sales Organization (CSO) segment is engaged in the operation and marketing support for medicinal products. The Health Care segment conducts site support institute (SMO) business, and provides health care information services. The Intellectual Property Development (IPD) segment develops and sells diagnostic products and orphan drugs.